Analytical Data
-
Gene name
HAVCR2
- Application
-
Alternative Names
HAVCR2;TIM3;TIMD3;Hepatitis A virus cellular receptor 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TDQ0
-
Expression Region
22-202aa
-
AA Sequence
SEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGPAETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIRIG
-
Molecular Weight
22.0kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HAVCR2, also known as Tim-3 (T cell immunoglobulin and mucin-domain containing-3), is an important immune checkpoint protein that has garnered significant attention in immunotherapy research. Originally identified as a marker of exhausted T cells in chronic infections and tumors, HAVCR2 plays a critical role in regulating immune responses, particularly in the context of T cell activation and tolerance. Studies have shown that the interaction of HAVCR2 with its ligand, galectin-9, can lead to T cell inhibition and promote tumor immune escape, making it a potential target for cancer immunotherapy. Furthermore, the modulation of HAVCR2 signaling pathways is believed to enhance anti-tumor immunity and improve therapeutic outcomes. As a result, recombinant HAVCR2 proteins are being explored for their potential to serve as biomarkers for disease progress and treatment response, as well as therapeutic agents in conjunction with other checkpoint inhibitors. This growing body of research underscores the significance of HAVCR2 in the tumor microenvironment and highlights its promise as a candidate for novel immunotherapeutic strategies aimed at reinvigorating exhausted T cells and combating malignancies.
